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Introduction 
Diminished blood flow to the brain and other organ systems may 
result from an impaired microcirculation due to pathological changes 
in the capillaries or reduced numbers of capillaries. The former are 
reflected in twisting, kinking, and looping of capillaries in the cerebral 
cortex [1-3]. Whether these changes progress to reduced capillary 
numbers by cellular atrophy has not been demonstrated and is not 
considered further here. However, the widespread reduced capillary 
density (CD) found in aged animals and people has been correlated 
with diminished levels of angiogenic growth factors (AGFs) [4-6]. 
The association between CD and AGFs during old age is the focus 
of this essay, which advances two ideas. 1) The reduced CD of old age 
may be the main, primary cause of many symptoms and signs of the 
elderly, i.e., the ‘lesser ailments of aging’. 2) A reduced CD may also be 
an underlying, secondary condition for other diseases associated with 
aging and may facilitate the action of factors postulated to cause them -- 
e.g. amyloid plaques, neurofibrillary tangles, etc. of Alzheimer’s disease 
(AD) or Lewy bodies, proposed malfunctioning mitochondria, etc. of 
Parkinson’s disease (PD). 
The Lesser Ailments of Aging 
People die from accidents and major diseases. The rest live on 
through old age with generally two sorts of complaints: chronic 
afflictions and/or lesser ailments. The former involve arthritis, diabetes, 
atrial fibrillation, Parkinson’s disease, or other distressing illnesses and 
are not a concern here. The latter, the lesser ailments, include minor 
symptoms, such as general muscle weakness, cold intolerance, memory 
lapses for names or words, and momentarily dozing, especially during 
the evening hours [6]. Also included are physical signs, such as wrinkled 
skin on the face and dorsum of the hands and the slow healing of 
bruises and abrasions. These symptoms and signs may share a common 
etiology which is the reduced capillary density that develops throughout 
the body during old age. 
As discussed elsewhere, a reduced CD in aged persons and animals 
has been described in over 40 reports and noted in many organ systems 
-- i.e., brain, muscle, skin, larynx, lung, colon, kidney and vasa vasorum 
[5,6]. Capillaries are formed and maintained by angiogenic growth 
factors (AGFs), whose levels are genetically programmed during early 
development and throughout life. A decline in AGFs in the aged has 
been described in seven other reports and noted in five organ systems 
-- i.e., the brain, muscles, kidney, mononuclear cells, and vein wall 
[5,6]. Among the AGFs are vascular endothelial growth factor (VEGF), 
fibroblast growth factors (FGFs), and other such factors. For this essay, 
the important aspect of these AGFs is that during old age their levels 
decline, resulting in a reduced capillary density in the tissues. Thus, the 
lesser ailments reflect a deficiency condition of AGFs, much like the 
reduced testosterone levels in elderly males. 
In the literature little mention has been made that the decline in 
the levels of AGFs in the elderly is genetically programmed. Whether 
amyloid plaques or other factors can also influence capillary density is 
unclear.
The Importance of Data 
In theory from the above analysis, the lesser ailments should be 
relieved or delayed by pro-angiogenic therapy -- e.g., recombinant forms 
of VEGF, FGF, or other angiogenic agents. This is a novel idea which 
must be introduced with persuasive data to be seriously considered by 
students of aging.
Merely listing a large number of papers sharing a common effect 
does not convey so convincingly their importance as does showing the 
relevant data. Age-linked changes are presented here in the form of 
‘data pairs’ -- i.e., values of CD or AGFs in adult animals or people vs. 
those in their aged counterparts. For example, Amenta et al. measured 
the capillary density in three areas of the brain of rats age 12 months vs. 
18 months old and reported reduction of the CD as follows -- frontal 
cortex: 122 vs. 71, occipital cortex: 130 vs. 82 and hippocampus: 113 vs. 
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58 [7]. Similarly, Haidet et al. compared the CD in three muscle areas 
of beagle dogs ages 2-3 years vs. 10-14 years and found the following 
-- gastrocnemius: 886 vs. 718, semitendinosus: 895 vs. 658, and triceps: 
959 vs. 805 [8].  These six sets of data are more persuasive than a 
generalization that papers by Amenta and Haidet show an age-linked 
reduce CD.  
As noted above, an examination of the research literature on aging 
and angiogenesis has disclosed 47 studies concerning CD and levels of 
AGFs. They have provided 80 data pairs showing age-linked reduced CD 
and declining AG. These paired figures have been presented elsewhere 
in tables and are the basis for a hypothesis that the reduced capillary 
numbers in the elderly account in part for their lesser ailments [4-6]. 
Cause and Effect 
The mere temporal association of two events -- here, a reduced 
CD throughout the body with aging and the age-linked development 
of LAA -- does not establish by itself cause and effect. Definitive proof 
would be showing that pro-angiogenesis therapy relieved or delayed 
onset of the lesser ailments. This proof has yet to be established. 
However, many experimental studies employing recombinant forms 
of AGFs support the hypothesis, as discussed in detail elsewhere [6,9]. 
For example, injection of VEGF or FGF into the normal cerebral cortex 
or ventricle of animals elicits cortical angiogenesis [10,11]. Occlusion 
of the femoral artery in an animal’s hind limb evokes ischemia there, 
which is relieved by local injections of AGFs [12]. Pro-angiogenesis 
treatment produced suggestive clinical improvement in subjects with 
intermittent claudication or cardiac insufficiency [13,14].  
The natural course of AGFs during animal/human life offers 
inferential support to the angiogenesis hypothesis. During early life, 
the rising levels of AGFs and the maturing microcirculation determine 
the development of various organ systems and account for the healthy 
functioning of the body. During old age, the waning levels of AGFs and 
the declining CD parallel the falling organ function and may logically 
account for the emerging symptoms and signs of aging -- notably the 
general muscle weakness of the lesser ailments. 
Alzheimer’s Disease 
Alzheimer’s disease is a dreaded development during aging in 
many persons. A reduced CD in subjects with AD is documented in 
five reports with 11 data pairs. Table 1 lists the CD in AD patients 
compared to values in an adult group or an aged group. Since all AD 
subjects here were elderly, a reduced CD found in them might merely 
reflect their age and not a specific effect on the AD aspect of their state of 
health. However, four data pairs suggest a slightly greater reduced CD 
in AD subjects compared with similarly aged persons -- e.g., reports #1 
(entorhinal cortex), #3, and #4. 
Other studies on AD patients suggest an impaired cerebral 
microcirculation. 1) Farkas et al. [15]  postulated that capillary 
dysfunction occurs in both Alzheimer’s diseases and Parkinson’s disease, 
based on finding a 2-fold increase in basement membrane deposits in these 
two conditions. 2) Hunter et al. found elevated numbers of degenerated 
string capillaries in AD brains but no overall reduced CD. However, 
the “total brain mass, determined at autopsy, was significantly less in 
AD compared to ND [non-demented] control groups” [16]. Cortical 
shrinkage may mask any reduced cerebral capillary counts, as discussed 
elsewhere [4]. 3) Sweat and Jicha reported that “capillary length-density 
was greater in AD...in the frontal neocortex” but postulated atrophy of the 
brain “as responsible” [17]. 4) Miners et al. reported a reduced CD and 
diminished levels of VEGF in cases of dementia with Lewy bodies [18]. 5) 
Parenthetically, Mateo et al. reported lower serum VEGF levels in subjects 
with Alzheimer’s disease [19].
Some gerontologists contend that AD involves a reduced cerebral 
microcirculation and have considered pro-angiogenesis therapy to aid 
this condition. For example, in 2004 Ward and LaManna wrote that “we 
now know angiogenesis is involved in Alzheimer’s disease” and several 
other neurological disorders [20]. They suggested that “controlling 
angiogenesis may also provide novel therapeutic approaches for 
treatment of these disorders.” In 2011, Wang et al. also wrote that “that 
VEGF should be pursued as a novel therapeutic agent for treatment of 
AD” [21]. These latter authors had found that therapeutic angiogenesis 
ameliorated the memory impairment in APP transgenic mouse model 
of Alzheimer’s disease. And in 2015, Baloyannis considered that 
“protection of the brain capillaries at the initial stages of the disease” 
might reduce “the pathological alterations” in AD [22].
Pro-Angiogenesis Therapy 
Three therapeutic approaches for easing the lesser ailments warrant 
consideration.
Authors Adults Aged AD
Mean capillary density mm/mm3 av. 38year (5) av. 74 year (5) av. 78 year (5)
Entorhinal cortex 148 124 111
Overall of 6 zones 124 102 101
Av. Capillary density mm/mm3 12-54 year (8) 67-95 year (8) 63-92 year (10)
Visual cortex, lamina 1 141 99 97
Visual cortex, av. of 6 laminae 251 212 206
% capil, surface area of total cortical field area 49 year (1) av. 79 year (3) av. 80 year (7)
Cortical areas 26.32% 18.95% 16.50%
Capillary density in test grid method  73 ± 4 year (6) 79 ± 12 year (8)
Frontal cortex  c. 28 c.21
Parietal cortex  c. 28 c.20
Vascular density index 23-90 year (6)  76-92 year (16)
Prefrontal cortex 94.6  75.4
Basal forebrain 86.8  42.7
Hippocampus 82.3  50.2
Motor sensory cortex 94.3  83.1
Note: c=value extrapolated from figure listed; other values listed here are cited in text; (  )=number of subjects
Table 1: Cerebral capillary density in adults/aged and AD subject.
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1) Employing recombinant angiogenic growth factors (VEGF, FGF 
or others) has been discussed at length in previous papers [4-6]. 
Their weaknesses for clinical use include being destroyed in the 
intestinal tract when administered orally and a short half- life 
in the circulation. These problems could be overcome in part 
by nasal administration in snuff or nose drops, as suggested 
and explained elsewhere [4,23].
2) Physical exercise evokes production of VEGF by striated muscles 
[5]. The released endogenous factor may enhance muscle 
function locally with new capillaries but also might reach the 
brain via the blood, increase the cerebral microcirculation, and 
improve memory and cognition. Exercise has been popularly 
recommended to improve mental sharpness [24].
3) A recent option is testing a long acting inhibitor of the type 5 
phosphodiesterase (PDE5), such as tadalafil/Cialis. 
Besides angiogenic growth factors (VEGF, FGF, etc.), several 
newly developed drugs in wide clinical use have been shown to elicit 
angiogenesis. They include sildenafil (Viagra) and tadalafil (Cialis), 
which are prescribed to treat various medical conditions, including 
erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and 
pulmonary arterial hypertension (PAH) [25]. The drugs’ intended 
effect in patients is to produce vasodilation, but in animal studies both 
have been shown also to induce capillary formation in ischemic tissues/
organs [26-31]. These drugs regulate a key intermediate in metabolic 
pathways leading to capillary formation, as outlined elsewhere 
[32]. They are effective when administered orally. For promoting 
angiogenesis, Cialis would be the superior PDE5 inhibitor because it 
has a longer biological half-life -- 17.5 h for Cialis vs. 4 h. for Viagra.
Conclusion
This short commentary has been a defense of the angiogenesis 
hypothesis of aging and the grouping together of the lesser ailments 
of aging (LAA). More difficult to support or prove is the idea that a 
reduced CD may facilitate the mechanisms or agents which have been 
proposed to cause AD and PD. It seems logical to believe that brain 
nutritionally impaired by a reduced cerebral microcirculation may be 
more vulnerable to specific pathological insults -- e.g., amyloid plaques, 
Lewy bodies, etc. But the reciprocal consideration suggests that a well-
nourished brain may slow the onset of the genetically fated cognitive 
decline. Thus pro-angiogenesis treatment seems a tenable approach for 
dealing with the LAA and indirectly with AD and PD. 
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